← Leaderboards
David T. Miyamoto
Massachusetts General Hospital
$3,300,055
Attributed
$3,642,108
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,642,108 · 2
By mechanism
R01$3,642,108 · 2
Top collaborators
- Sheung Chee Thomas Ng1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Maha Farhat$7,486,819
- Aria F Olumi$5,702,955
- Gary Jay Brenner$3,851,453
- Hak Soo Choi$7,452,919
- Hakho Lee$15,122,007
Others in their field
Other Rising Stars on “Therapy Resistant”
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Rino Rappuoli · Washington University$14,702,884
- Xuping Xie · University Of Texas Med Br Galveston$14,015,062
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
- Fumiaki Yokokawa · University Of Texas Med Br Galveston$7,180,989
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
Research focus
Therapy ResistantMalignant NeoplasmsNeoplasm Circulating CellsResponsePrognosisPatient MonitoringImageMonitorPatient SelectionResistanceTumorTreatment ResponsePredictive SignatureCancer PatientClinical TrialsCancer BiologyLiquid BiopsyExpression ProfilingBloodFollow-UpBladder NeoplasmBladderEvolutionGene Expression Profile
Grant awards (5)
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer$1,207,297
R01 · FY2025 · CA · contact PI
Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients$684,107
R01 · FY2025 · CA
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer$567,228
R01 · FY2024 · CA · contact PI
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer$586,396
R01 · FY2023 · CA · contact PI
Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer$597,080
R01 · FY2022 · CA · contact PI